title: A medical nutriment has supportive value in the treatment of colorectal cancer.
abstract: MSC (Avemar) is a medical nutriment of which preclinical and observational clinical studies suggested an antimetastatic activity with no toxicity. This open-label cohort trial has compared anticancer treatments plus MSC (9 g once daily) vs anticancer treatments alone in colorectal patients, enrolled from three oncosurgical centres; cohort allocation was on the basis of patients' choice. Sixty-six colorectal cancer patients received MSC supplement for more than 6 months and 104 patients served as controls (anticancer therapies alone): no statistical difference was noted in the time from diagnosis to the last visit between the two groups. End-point analysis revealed that progression-related events were significantly less frequent in the MSC group (new recurrences: 3.0 vs 17.3%, P<0.01; new metastases: 7.6 vs 23.1%, P<0.01; deaths: 12.1 vs 31.7%, P<0.01). Survival analysis showed significant improvements in the MSC group regarding progression-free (P=0.0184) and overall survivals (P=0.0278) probabilities. Survival predictors in Cox's proportional hazards were UICC stage and MSC treatment. Continuous supplementation of anticancer therapies with MSC for more than 6 months is beneficial to patients with colorectal cancer in terms of overall and progression-free survival.
authors.affiliation: Department of Surgery and Vascular Surgery, Uzsoki Teaching Hospital of Budapest, Hungary.
authors.forename: F
authors.initials: F
authors.lastname: Jakab
authors.forename: Y
authors.initials: Y
authors.lastname: Shoenfeld
authors.forename: A
authors.initials: A
authors.lastname: Balogh
authors.forename: M
authors.initials: M
authors.lastname: Nichelatti
authors.forename: A
authors.initials: A
authors.lastname: Hoffmann
authors.forename: Zs
authors.initials: Z
authors.lastname: Kahán
authors.forename: K
authors.initials: K
authors.lastname: Lapis
authors.forename: A
authors.initials: A
authors.lastname: Mayer
authors.forename: P
authors.initials: P
authors.lastname: Sápy
authors.forename: F
authors.initials: F
authors.lastname: Szentpétery
authors.forename: A
authors.initials: A
authors.lastname: Telekes
authors.forename: L
authors.initials: L
authors.lastname: Thurzó
authors.forename: A
authors.initials: A
authors.lastname: Vágvölgyi
authors.forename: M
authors.initials: M
authors.lastname: Hidvégi
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy / Q000601:surgery; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010936:Plant Extracts / Q000494:pharmacology*; D016896:Treatment Outcome; D014908:Triticum / Q000737:chemistry
chemical_list: D000970:Antineoplastic Agents; C113915:Avemar; D010936:Plant Extracts